CNBX Pharmaceuticals Reports No Revenue, Minimal Net Loss in Q3

TL;DR

CNBX is a pre-revenue pharma play with no real financial movement, making it a high-risk bet on future development.

AI Summary

CNBX Pharmaceuticals Inc. reported no revenue for the three and nine months ended May 31, 2025, and May 31, 2024, indicating a continued pre-revenue stage of development. The company incurred a net loss of $1,000 for the three months ended May 31, 2025, a significant improvement from the $1,000 net loss reported for the same period in 2024. For the nine months ended May 31, 2025, the net loss was $1,000, also an improvement from the $1,000 net loss in the prior year. Key business changes include a stable common stock count at 10,000,000 shares outstanding as of May 31, 2025, and August 31, 2024. The company's accumulated deficit remained at $1,000 as of May 31, 2025, and August 31, 2024. The strategic outlook remains focused on its pharmaceutical preparations, though specific advancements or new initiatives are not detailed in the provided excerpt. The primary risk highlighted is the lack of revenue generation and the ongoing net losses, which are typical for a development-stage pharmaceutical company.

Why It Matters

For investors, CNBX's continued lack of revenue and minimal net loss signals it remains a highly speculative, pre-commercial entity. The absence of significant financial activity suggests either a very early stage of development or a dormant operational status, which could impact future funding and market valuation. Employees and customers are largely unaffected as there's no commercial product or significant operational footprint. In the broader pharmaceutical market, CNBX's status highlights the challenges smaller players face in bringing products to market, especially in competitive therapeutic areas, without substantial capital or clinical progress.

Risk Assessment

Risk Level: high — The risk level is high because CNBX Pharmaceuticals Inc. reported no revenue for both the three and nine months ended May 31, 2025, and May 31, 2024. This indicates a complete lack of commercial operations and reliance on external funding, which is not detailed. The company also reported an accumulated deficit of $1,000 as of May 31, 2025, and August 31, 2024, signifying historical losses.

Analyst Insight

Investors should approach CNBX with extreme caution, recognizing it as a highly speculative investment. Given the lack of revenue and minimal financial activity, potential investors should await concrete evidence of clinical progress, product development, or significant capital raises before considering a position.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $0 — Revenue (for three and nine months ended May 31, 2025, indicating pre-revenue status)
• $1,000 — Net Loss (for three months ended May 31, 2025, an improvement from prior year)
• $1,000 — Net Loss (for nine months ended May 31, 2025, an improvement from prior year)
• 10,000,000 — Common Stock Shares (outstanding as of May 31, 2025, showing stability)
• $1,000 — Accumulated Deficit (as of May 31, 2025, indicating historical losses)

Key Players & Entities

• CNBX Pharmaceuticals Inc. (company) — filer of the 10-Q
• $1,000 (dollar_amount) — net loss for three months ended May 31, 2025
• $1,000 (dollar_amount) — net loss for nine months ended May 31, 2025
• 10,000,000 (dollar_amount) — common stock shares outstanding as of May 31, 2025
• $1,000 (dollar_amount) — accumulated deficit as of May 31, 2025
• 03 Life Sciences (company) — organization name
• NV (regulator) — state of incorporation
• Bethesda, MD (company) — business address location
• Cannabics Pharmaceuticals Inc. (company) — former company name
• American Mining Corp (company) — former company name

FAQ

Risk Factors

• Pre-Revenue Status and Net Losses [high — financial]: CNBX Pharmaceuticals Inc. reported $0 revenue for the three and nine months ended May 31, 2025. The company incurred a net loss of $1,000 for the three months ended May 31, 2025, and $1,000 for the nine months ended May 31, 2025. The accumulated deficit remained at $1,000 as of May 31, 2025.

Industry Context

The pharmaceutical preparations industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this sector often operate in a pre-revenue stage for extended periods, relying on external funding to finance their operations and clinical trials. The competitive landscape is intense, with established players and emerging biotechs vying for market share and therapeutic breakthroughs.

Regulatory Implications

As a pharmaceutical company, CNBX is subject to stringent regulations from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP), clinical trial protocols, and drug approval processes are critical. Any delays or failures in regulatory approvals can significantly impact the company's development timeline and financial viability.

What Investors Should Do

1. Monitor R&D Progress
2. Assess Burn Rate and Funding

Key Dates

• 2025-05-31: End of Nine Months Period — Indicates the reporting period for the 10-Q filing, showing $0 revenue and a $1,000 net loss for the nine months.
• 2025-05-31: Common Stock Outstanding — 10,000,000 shares outstanding, consistent with the prior period, indicating no significant equity dilution or issuance.
• 2025-05-31: Accumulated Deficit — Stood at $1,000, reflecting the company's historical losses since inception.
• 2024-08-31: Fiscal Year End — Previous fiscal year end, providing a comparative baseline for the current reporting period.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial information and analysis presented.)

Pre-revenue stage

A phase in a company's lifecycle where it has not yet generated any sales or revenue from its products or services, typically common for development-stage companies. (CNBX Pharmaceuticals Inc. is currently in this stage, highlighting its reliance on funding for operations and development.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (CNBX reported a net loss of $1,000 for the three and nine months ended May 31, 2025, indicating ongoing operational costs without corresponding revenue.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income since its inception. (CNBX's accumulated deficit of $1,000 as of May 31, 2025, shows the historical extent of its unrecovered losses.)

Year-Over-Year Comparison

CNBX Pharmaceuticals Inc. reported $0 revenue for both the three and nine months ended May 31, 2025, and the comparable periods in the prior year, indicating no change in its pre-revenue status. The net loss for the three months ended May 31, 2025, was $1,000, an improvement from the $1,000 net loss in the prior year's period. Similarly, the nine-month net loss of $1,000 also showed an improvement from the prior year's $1,000 net loss. The number of common shares outstanding remained stable at 10,000,000, and the accumulated deficit was unchanged at $1,000, suggesting minimal operational or financial changes impacting these key metrics year-over-year.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 14, 2025 regarding CNBX Pharmaceuticals Inc. (CNBX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR